Will Lu-177-anti-PSMA be the next Xofigo?

Xofigo® (radium Ra-223 dichoride) has been a game-changer in the treatment of prostate cancer metastatic to bone. Not only does it provide significant pain palliation and reduce skeletal-related adverse events, but it slows down progression of the disease, increasing median survival by about 30 percent. … READ MORE …

How much time is there to make decisions about treatment for low-risk patients?

In recent years there has been a widely acknowledged, if unconfirmed, assumption that men initially diagnosed with low-risk prostate cancer (clinical stage T1-2a, PSA < 10 ng/ml; and Gleason 3 + 3 = 6 or lower) had plenty of time to come to a good decision about their management options, and did not need to rush such decisions. … READ MORE …

“Normal” sexual functionality after a radical prostatectomy — it’s not very likely

According to a report on the Science Daily web site today, a presentation at the ongoing European Association of Urology (EAU) meeting in Madrid, Spain, suggests that the ability to regain normal erectile and sexual function after a radical prostatectomy is actually rather worse than one might have thought. … READ MORE …

Smoking isn’t good for men with prostate cancer (redux)

Back in 2011 we commented on a report indicating that men who continued smoking after initial treatment for prostate cancer (or who were smokers up to 10 years prior to their treatment) were at significantly higher risk for prostate cancer progression than non-smokers. … READ MORE …

Early data from an Australian registry of HIFU-treated patients

We should preface the following commentary by stating that there is no doubt that it takes time to learn to use high-intensity focused ultrasound (HIFU) really well as a form of first-line treatment for localized prostate cancer. This is hardly surprising. … READ MORE …

Familial risk for prostate cancer ups risk for breast cancer too

Just a few days ago, a paper in Cancer reported that familial risk for breast cancer in women appeared to be affected not only by a familial history of breast cancer but also by a familial history of prostate cancer among close family members. … READ MORE …

ADT, patient survival, and serum testosterone levels after initiation of treatment

Over the years there have been multiple debates about whether different types of androgen deprivation therapy (ADT) really do or don’t extend the survival of men with advanced prostate cancer of differing types and whether the degree to which ADT initially suppresses serum testosterone levels affects that survival. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,253 other followers